The takeaway
BridgeBio Pharma Inc shows a pronounced seasonal pattern over 7 years of data — strongest in June (+11.7%) and softest in September (−4.2%).
Right now
In July, the stock has risen 57% of years, averaging +12.4%, about +10.2 pts better than the S&P 500.
The full picture
BridgeBio Pharma Inc's most dependable month has been June, higher in 5 of 7 years; September has been its least reliable, up just 29% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | — | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in June (+11.4 pts); it has trailed the market most in April (−5.1 pts).
“vs S&P” is BridgeBio Pharma Inc’s average for a month minus the S&P 500’s average for that same month — isolating BridgeBio Pharma Inc’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, June has closed higher 80% of the time versus 71% across the last 7 years — the pattern is strengthening.
Figures are the typical (median) June return and how often it rose — the last 5 years versus the last 7(the heatmap’s default window). This verdict stays anchored to that 7-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
The seasonal story is really one month's story — June. It has closed higher in 5 of 7 Junes, a concentration the rest of the calendar can't touch.
The strength looks broad-based rather than freakish: its average (+11.7%) and median (+12.9%) sit close together, so no single blow-out year is flattering the figure. That reliability comes with real swings, mind — even June ranges by 16.1% from year to year, so any single year can land far from the average. Better still, that strength is the stock's own and not just a buoyant market — June has outpaced the S&P 500 by +11.4 points on average. Few peers keep such company in June — the typical stock clears it just 52% of the time.
It doesn't stand entirely alone — February, August, and October have leaned firm as well, if less emphatically. On the other side of the ledger, September has been the soft spot — the weakest of 4 months that average a loss (−4.2%), and the edge isn't year-round — the stock has trailed the S&P 500 in April, May, and September. Its roughest month on record was a −57.8% December in 2021 — a reminder of how hard even a seasonal name can fall.
If anything it has sharpened recently — the last five Junes run ahead of the earlier years.
For a stock this dependable in June, the sharper question is the rest of the year — outside its strong stretch, the calendar gives far less to lean on. With a short 7-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (June), its worst (September), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2019 its best month (June, +11.7%) has run well ahead of its worst (September, −4.2%) — the heatmap above shows how steady that gap has been year to year.
June has been the strongest, averaging +11.7% and closing higher in 5 of 7 years since 2019.
It's the weakest, averaging −4.2% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade